Surgical Pathology, Gastrointestinal Pathology, Gynecologic Pathology
Dr. Orucevic's research is focused on the development of practical statistical models designed to predict prognosis of patients with breast cancer that can be used in the therapeutic decision making process. Working with Dr. Heidel, she is developing calculators that can predict breast cancer genomic test results, such as Oncotype DX and Mammaprint, without performing the tests themselves. These tests are expensive (~$4,000) and are not affordable for the majority of patients worldwide. They are utilized in ~30% of eligible breast cancer patients in the USA but play an important role as "precision medicine."
Her recently published calculator for prediction of Oncotype DX test results is widely used. The research paper describing the calculator was the most downloaded publication for the "Breast Cancer Research and Treatment" journal in 2017.
University of Sarajevo Medical School, Bosnia and Herzegovina, 1978-1983
Anatomic and Clinical Pathology, Rush University Medical Center, Chicago, IL,1998-2002
Surgical Pathology, Loyola University Medical Center, Maywood, IL, 2002-2003
The Royal College of Physicians and Surgeons of Canada in Anatomic Pathology, 2002
The American Board of Pathology in Combined Anatomic Pathology and Clinical Pathology, 2002
Cochrane K, Bell JL, Heidel RE, Orucevic A.
Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis-Lessons learned from a 12-year analysis of the National Cancer Database. The Breast Journal. 2021 Feb;27(2):165-169. Epub 2021 Jan 22.
Orucevic A, Bell JL, King M, McNabb AP, Heidel RE.
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast (Edinburgh, Scotland). 2019 May 10;46:116-125.
Johnson M, Casillas M Jr, Orucevic A.
Adenosquamous carcinoma of the anus: An uncommon malignancy presenting a treatment challenge. The American Surgeon. 2018 Jul 1;84(7):e248-e250.
Orucevic A, Bell JL, McNabb AP, Heidel RE.
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Research and Treatment. 2017 May;163(1):51-61. Epub 2017 Feb 27.
Bhat S, Orucevic A, Woody C, Heidel RE, Bell JL.
Evolving trends and influencing factors in mastectomy decisions. The American Surgeon. 2017 Mar 1;83(3):233-238.
Kleppe KL, Gray KD, Stancher JA, Duncan LD, Vaughan JW, Orucevic A.
A rare case of plasmablastic lymphoma mimicking adenocarcinoma of the sigmoid colon. The American Surgeon. 2016 Aug;82(8):178-180.
Orucevic A, Bell J. Prognostic significance of age, histologic subtype, tumor size and nodal status on breast cancer specific survival of “clinical low risk” grade 1 ER+/HER2- breast carcinoma patients - SEER analysis 2010-2012 Presented at San Antonio Breast Cancer Symposium; 2020 Dec 8-12; San Antonio, TX.
Riedinger C, Riley W, Scheiderer A, Heidel E, Orucevic A, Boone J, Kilgore LC, Kimball K. Reading between the lines: The interpretation of IHC staining for MMR proteins and its effect on clinical decision making in endometrial cancer. Presented at *Society of Gynecologic Oncology Annual Meeting on Women's Cancer; 2020 Mar 28-31; Toronto, Canada.
Riedinger CJ, Riley WL, Scheiderer A, Orucevic A, Kimball KJ. Universal endometrial tumor testing is superior to clinical and age restricted tumor testing for the identification of Lynch syndrome. Presented at American College of Obstetrics and Gynecology Districts IV, VII & XI Annual Meeting; 2019 Sep 27-29; New Orleans, LA.
Scheiderer AN, Orucevic A. Positive antimitochondrial antibodies in patients with no histologic evidence of primary biliary cholangitis on liver biopsy: A rare scenario observed in a series of five patients. Presented at College of American Pathologists Annual Meeting; 2019 Sep 21-25; Orlando, FL.
Scheiderer AN, Kimball KJ, Kilgore, LC, Snyder DH, Orucevic A. Heterogenous immunohistochemical staining pattern of mismatch repair proteins in endometrial cancer: Is it time to re-evaluate the guidelines? Presented at United States and Canadian Academy of Pathology Annual Meeting; 2019 Mar 16-21; National Harbor, MD.
Cochrane K, Heidel RE, Bell JL, Orucevic A. Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis – lessons learned from a twelve year analysis of the National Cancer Data Base. Presented at San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX.
Scheiderer AN, Kimball KJ, Kilgore LC, Snyder DH, Orucevic A. MSH6 mismatch repair protein immunohistochemical expression in endometrial cancer and Lynch syndrome: An academic institution 5 year experience. Presented at College of American Pathologists Annual Meeting; 2018 Oct 20-24; Chicago, IL.
Cochrane K, Kimball K, Orucevic A. Triple synchronous ovarian carcinomas: An unlikely association of serous carcinoma with large cell neuroendocrine carcinoma and granulosa cell tumor. Presented at European Society of Gynaecological Oncology Lyon State of the Art Conference; 2018 Oct 4-6; Lyon, France.
Orucevic A, Heidel R, Bell JL. Using the National Cancer Data Base (NCDB) and Oncotype DX data to predict adjuvant therapy effect on overall survival (OS) of N0 & N1 breast cancer patients. Presented at American Society of Clinical Oncology Annual Meeting; 2018 Jun 1-5; Chicago, IL.
Johnson M, Casillas MA, Orucevic A. Adenosquamous carcinoma of the anus: An uncommon malignancy presenting a treatment challenge. Presented at Southeastern Surgical Congress; 2018 Feb 10-13; Tampa, FL.
Orucevic A, Heidel RE, Bell JL. Outcomes of patients with invasive breast cancer (IBC) refusing standard cancer treatments: 10-year analysis of the National Cancer Data Base (NCDB). Presented at San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX.
Rose CE, Heidel RE, Bell JL, Orucevic A. Primary neuroendocrine carcinoma of the breast – lessons learned from a ten year analysis of the National Cancer Data Base (NCDB). Presented at San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX.
Rose CE, Charles A, Orucevic A. Primary small cell carcinoma of the breast with merkel cell carcinoma immunophenotype. Presented at College of American Pathologists, The Pathologists Meeting; 2017 Oct 8-11; National Harbor, MD.
Bhat S, Heidel R, Bell J, Orucevic A. Influencing factors and evolving trends for contralateral prophylactic mastectomy in breast cancer patients. Presented at 2nd World Congress on Breast Cancer; 2016 Sep 19-21; Phoenix, AZ.
McNeil M, Heidel R, Bell JL, Orucevic A. Factors influencing decisions of breast cancer patients to follow-up on recommendations for genetic counselling - The University of Tennessee Medical Center experience. Presented at 2nd World Congress on Breast Cancer (Invited Lecture); 2016 Sep 19-21; Phoenix, AZ.
Orucevic A. The predictive and prognostic multigene breast cancer assays used in the clinical practice in the United States: Analysis of the National Cancer Data Base. Presented at 2nd World Congress on Breast Cancer (Invited Lecture); 2016 Sep 19-21; Phoenix, AZ.
Gage HM, Duncan LD, Aljadir D, Orucevic A. Primary breast cancer or metastatic atypical carcinoid tumor: An unlikely diagnostic challenge. Presented at College of American Pathologists, CAP16 The Pathologists' Meeting; 2016 Sep 25-28; Las Vegas, NV.
Patel P, Samavedy R, Orucevic A. Remicade (infliximab) induced autoimmune hepatitis: A rare recently recognized complication of anti-TNFa agents used for treatment of psoriatic arthritis. Presented at College of American Pathologists, CAP16 The Pathologists' Meeting; 2016 Sep 25-28; Las Vegas, NV.
Orucevic A. What can be learned from the "big data" analysis from the National Cancer Data Base. Presented at Tennessee Oncology Data Analysts Association (TODAA) (Invited Lecture); 2016 Sep 15-16; Knoxville, TN.Top
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2019